삼성서울병원

Ko En

혈액종양내과 선종무 교수

진료분야
폐암, 식도암
진료일정 06 月
날짜
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
오전
오후
진료일정 07 月
날짜
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
오전
오후

학력

학력
2011.02 서울대학교 의과대학원 박사학위 취득
2005.02 서울대학교 의과대학원 석사학위 취득
2000.02 서울대학교 의과대학 졸업

경력

경력
2022.03 ~현재 삼성서울병원 혈액종양내과 교수
2016.03 ~ 2022.02 삼성서울병원 혈액종양내과 부교수
2012.03 ~ 2016.02 삼성서울병원 혈액종양내과 조교수
2010.03 ~ 2012.02 삼성서울병원 혈액종양내과 임상조교수
2009.03 ~ 2010.02 삼성서울병원 혈액종양내과 임상강사
2008.05 ~ 2009.02 서울대학교병원 혈액종양내과 임상강사
2005.02 ~ 2008.04 육군 군의관
2001.03 ~ 2005.02 서울대학교병원 레지던트
2000.03 ~ 2001.02 서울대학교병원 인턴

학회활동

학회활동
대한암학회
대한폐암학회
미국임상암학회(American Society of Clinical Oncology)
세계폐암학회(International Association for the study of Lung Cancer)
한국임상암학회
항암요법연구회
  • FUTURE ONCOL 2024 10.2217/fon-2022-1148 LEAP-014: first-line lenvatinib plus pembrolizumab plus chemotherapy in advanced/metastatic esophageal squamous cell carcinoma Sun, JM; Adenis, A; Enzinger, PC; Shah, MA; Kato, K; Bennouna, J; Doi, T; Hawk, NN; Yu, L; Shah, SK; Bhagia, P; Shen, L
    View PubMed
  • J CACHEXIA SARCOPENI 2024 10.1002/jcsm.13462 Prognostic impact of muscle mass loss in elderly patients with oesophageal cancer receiving neoadjuvant chemoradiation therapy Jang, JY; Oh, D; Noh, JM; Sun, JM; Kim, HK; Shim, YM
    View PubMed
  • LUNG CANCER 2024 10.1016/j.lungcan.2024.107536 Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis Jung, HA; Park, B; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • EBIOMEDICINE 2024 10.1016/j.ebiom.2024.105062 Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer Park, S; Hong, TH; Hwang, S; Heeke, S; Gay, CM; Kim, J; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Cho, JH; Choi, YS; Kim, J; Shim, YM; Kim, HK; Byers, LA; Heymach, JV; Choi, YL; Lee, SH; Park, K
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2023.897 Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study Park, S; Lee, Y; Lee, J; Min, YW; Kim, HK; Choi, JY; Jung, HA; Choi, YS; Choi, YL; Shim, YM; Sun, JM
    View PubMed
  • CANCER-AM CANCER SOC 2024 10.1002/cncr.35175 Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B Hong, J; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Sinn, DH; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2023.461 First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALKRearrangement: Real-World Data Jeon, Y; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • TRANSL LUNG CANCER R 2023 10.21037/tlcr-23-643 Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC) Choi, DH; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH
    View PubMed
  • ESMO OPEN 2023 10.1016/j.esmoop.2023.102068 Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • ESOPHAGUS-TOKYO 2023 10.1007/s10388-023-01031-x Prognostic role of pathologic status other than complete response after neoadjuvant therapy followed by surgery in esophageal squamous cell carcinoma Park, SY; Lee, JH; Oh, D; Sun, JM; Yun, JH; Jeon, YJ; Cho, JH; Choi, YS; Zo, JI; Shim, YM; Kim, HK
    View PubMed
  • CANCERS 2023 10.3390/cancers15225450 Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations Jun, S; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Cho, J; Jung, HA
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2023.403 Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement Jeon, Y; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • CANCER-AM CANCER SOC 2023 10.1002/cncr.35059 Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer Park, S; Kim, YJ; Min, YJ; Mortimer, PGS; Kim, HJ; Smith, SA; Dean, E; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2023.05.027 Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer Jung, HA; Ku, BM; Kim, YJ; Park, S; Sun, JM; Lee, SH; Ahn, JS; Cho, JH; Kim, HK; Choi, YS; Choi, YL; Shin, SH; Jeong, BH; Um, SW; Kim, H; Kim, K; Ahn, MJ; Kim, J
    View PubMed
  • TRANSL LUNG CANCER R 2023 10.21037/tlcr-23-160 Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2023.03.024 Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC Hong, TH; Bang, YH; Joe, CY; Hwang, S; Lee, B; Lee, N; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Choi, YL; Lee, SH
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.1344 The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.388 EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • ADV SCI 2023 10.1002/advs.202204378 Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8(+) T Cells Lee, SH; Kim, Y; Jeon, BN; Kim, G; Sohn, J; Yoon, Y; Kim, S; Kim, Y; Kim, H; Cha, HG; Lee, NE; Yang, HYS; Chung, JY; Jeong, AR; Kim, YY; Kim, SG; Seo, Y; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, H; Yoon, KW
    View PubMed
  • JAMA NETW OPEN 2023 10.1001/jamanetworkopen.2023.2002 Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020 Chi, SA; Yu, H; Choi, YL; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Choi, DH; Kim, K; Jung, HA; Park, K
    View PubMed
  • J IMMUNOTHER CANCER 2023 10.1136/jitc-2022-005509 Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment Kim, H; Park, S; Han, KY; Lee, N; Kim, H; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH; Park, WY
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2022.10.008 A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21) Jung, HA; Kim, M; Kim, HS; Kim, JH; Choi, YH; Cho, J; Park, JH; Park, KU; Ku, BM; Park, S; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • INT J RADIAT ONCOL 2023 10.1016/j.ijrobp.2022.07.018 Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Kim, CG; Yoon, HI; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Shin, EC; Ahn, MJ
    View PubMed
  • THORAC CANCER 2023 10.1111/1759-7714.14796 Adjuvant chemotherapy in node-positive patients after esophagectomy for esophageal squamous cell carcinoma Jeon, YJ; Cho, JH; Choi, YS; Shim, YM; Sun, JM; Kim, HK
    View PubMed
  • CANCER MED-US 2022 10.1002/cam4.5460 Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma Park, S; Cha, H; Kim, HS; Lee, B; Kim, S; Kim, TM; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH
    View PubMed
  • ISCIENCE 2022 10.1016/j.isci.2022.105358 Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma Jeong, HO; Lee, H; Kim, H; Jang, J; Kim, S; Hwang, T; Choi, DWY; Kim, HS; Lee, N; Lee, YM; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SM; Lee, SH
    View PubMed
  • CLIN CANCER RES 2022 10.1158/1078-0432.CCR-22-0879 Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC br Jung, HA; Lim, J; Choi, YL; Lee, SH; Joung, JG; Jeon, YJ; Choi, JW; Shin, S; Cho, JH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Han, JH; Park, WY; Kim, J; Park, K
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.21.01926 Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study Shen, L; Kato, K; Kim, SB; Ajani, JA; Zhao, K; He, ZY; Yu, XM; Shu, YQ; Luo, Q; Wang, JF; Chen, ZD; Niu, ZX; Zhang, LZ; Yi, TN; Sun, JM; Chen, JH; Yu, GH; Lin, CY; Hara, H; Bi, Q; Satoh, T; Pazo-Cid, R; Arkenau, HT; Borg, C; Lordick, F; Li, LY; Ding, NN; Tao, AY; Shi, JW; Van Cutsem, E
    View PubMed
  • J THORAC ONCOL 2022 10.1016/j.jtho.2022.04.001 Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial Lee, J; Koh, J; Kim, HK; Hong, S; Kim, K; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.21.02010 Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer Park, S; Ock, CY; Kim, H; Pereira, S; Park, S; Ma, M; Choi, S; Kim, S; Shin, S; Aum, BJ; Paeng, K; Yoo, D; Cha, H; Park, S; Suh, KJ; Jung, HA; Kim, SH; Kim, YJ; Sun, JM; Chung, JH; Ahn, JS; Ahn, MJ; Lee, JS; Park, K; Song, SY; Bang, YJ; Choi, YL; Mok, TS; Lee, SH
    View PubMed
  • CLIN CANCER RES 2022 10.1158/1078-0432.CCR-21-3646 Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study Jung, HA; Park, S; Choi, YL; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • INT J RADIAT ONCOL 2022 10.1016/j.ijrobp.2022.02.003 Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Yoon, HI; Moon, H; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Ahn, MJ; Shin, EC
    View PubMed
  • CANCER MED-US 2022 10.1002/cam4.4663 Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors Kwon, M; Ku, BM; Olsen, S; Park, S; Lefterova, M; Odegaard, J; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • EUR J CANCER 2022 10.1016/j.ejca.2022.03.034 Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer Park, S; Noh, JM; Choi, YL; Chi, SA; Kim, K; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • J THORAC ONCOL 2022 10.1016/j.jtho.2021.11.025 A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors Cho, BC; Han, JY; Kim, SW; Lee, KH; Cho, EK; Lee, YG; Kim, DW; Kim, JH; Lee, GW; Lee, JS; Shim, BY; Kim, JS; Chun, SH; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Lee, Y; Lee, DH; Kang, JA; Lee, N; Kwon, MJ; Espenschied, C; Yablonovitch, A; Ahn, MJ
    View PubMed
  • CANCER-AM CANCER SOC 2022 10.1002/cncr.34176 Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma Park, S; Oh, D; Choi, YL; Chi, SA; Kim, K; Ahn, MJ; Sun, JM
    View PubMed
  • ESMO OPEN 2022 10.1016/j.esmoop.2022.100385 Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study Park, S; Sun, JM; Choi, YL; Oh, D; Kim, HK; Lee, T; Chi, SA; Lee, SH; Choi, YS; Jung, SH; Ahn, MJ; Ahn, YC; Park, K; Shim, YM
    View PubMed
  • ONCOLOGY-BASEL 2022 10.1159/000516813 Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor Ku, BM; Kim, YJ; Park, D; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Sun, JM
    View PubMed
  • INVEST NEW DRUG 2022 10.1007/s10637-021-01121-6 ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer Ku, BM; Heo, JY; Kim, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.306 Long-term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • EUR J CANCER 2021 10.1016/j.ejca.2021.09.037 Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience Lee, YP; Jeong, BH; Eun, Y; Kang, CI; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-691 Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment Hwang, S; Hong, TH; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Lee, SH
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-531 Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system Jung, HA; Jeong, O; Chang, DK; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • LANCET 2021 Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study Sun, JM; Shen, L; Shah, MA; Enzinger, P; Adenis, A; Doi, T; Kojima, T; Metges, JP; Li, ZG; Kim, SB; Cho, BC; Mansoor, W; Li, SH; Sunpaweravong, P; Maqueda, MA; Goekkurt, E; Hara, H; Antunes, L; Fountzilas, C; Tsuji, A; Oliden, VC; Liu, Q; Shah, S; Bhagia, P; Kato, K
    View PubMed
  • J MED INTERNET RES 2021 10.2196/28695 Feasibility of an Interactive Health Coaching Mobile App to Prevent Malnutrition and Muscle Loss in Esophageal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy: Prospective Pilot Study Yang, K; Oh, D; Noh, JM; Yoon, HG; Sun, JM; Kim, HK; Zo, JI; Shim, YM; Ko, H; Lee, J; Kim, Y
    View PubMed
  • NANOMED-NANOTECHNOL 2021 10.1016/j.nano.2021.102415 Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model Koh, J; Kim, S; Lee, SN; Kim, SY; Kim, JE; Lee, KY; Kim, MS; Heo, JY; Park, YM; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Yang, S; Ha, SJ; Lim, YT; Ahn, MJ
    View PubMed
  • J CACHEXIA SARCOPENIA MUSCLE 2021 10.1002/jcsm.12747 Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer Yoon1, HG; Oh, D; Noh, JM; Cho, WK; Sun, JM; Kim, HK; Zo, JI; Shim, YM; Kim, K
    View PubMed
  • CANCER 2021 10.1002/cncr.33571 High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program Park1, S; Olsen, S; Ku, BM; Lee, MS; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ
    View PubMed
  • J KOREAN NEUROSURG SOC 2021 10.3340/jkns.2020.0135 Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery Lee1, MH; Cho, KR; Choi, JW; Kong, DS; Seol, HJ; Nam, DH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Lee, JI
    View PubMed
  • KOREAN J INTERN MED 2021 10.3904/kjim.2019.161 Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer Lim1, SH; Sun, JM; Hong, J; Oh, D; Ahn, YC; Chung, MK; Jeong, HS; Son, YI; Ahn, MJ; Baek, CH; Park, K
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-20-1128 Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors Kim1, H; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • EUR J IMMUNOL 2021 10.1002/eji.202048966 Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer Ku1, BM; Kim, Y; Lee, KY; Kim, SY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • IMMUNE NETW 2020 10.4110/in.2020.20.e48 Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs Kim1, KH; Hur, JY; Koh, J; Cho, J; Ku, BM; Koh, JY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Shin, EC
    View PubMed
  • SCI REP-UK 2020 10.1038/s41598-020-76130-1 Regulatory -(FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer Koh1, J; Hur, JY; Lee, KY; Kim, MS; Heo, JY; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018 Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status Lee1, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • EUR J CARDIO-THORAC 2020 10.1093/ejcts/ezaa181 Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation Lee1, J; Choi, JY; Lim, SW; Ahn, MJ; Park, K; Zo, JI; Shim, YM; Oh, D; Sun, JM
    View PubMed
  • J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199 Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity Hong1, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY
    View PubMed
  • TRANSL LUNG CANCER R 2020 10.21037/tlcr-20-379 The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer Jung1, HA; Woo, SY; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • CANCER IMMUNOL IMMUN 2020 10.1007/s00262-020-02766-7 Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect Lee1, J; Kim, B; Jung, HA; Choi, YL; Sun, JM
    View PubMed
  • BIOLOGY-BASEL 2020 10.3390/biology9100326 Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations? Jung1, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2020.278 EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation Park1, S; Ku, BM; Jung, HA; Sun, JM; Ahn, JS; Lee, SH; Park, K; Ahn, MJ
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.06.017 A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy Park1, S; Lee, MH; Seong, M; Kim, ST; Kang, JH; Cho, BC; Lee, KH; Cho, EK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER 2020 10.1002/cncr.33048 Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy Park1, S; Shim, J; Mortimer, PGS; Smith, SA; Godin, RE; Hollingsworth, SJ; Kim, HJ; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K
    View PubMed
  • BRIT J CANCER 2020 10.1038/s41416-020-01074-2 Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck Kim1, HR; Kang, HN; Yun, MR; Ju, KY; Choi, JW; Jung, DM; Pyo, KH; Hong, MH; Ahn, MJ; Sun, JM; Kim, HS; Kim, J; Yoo, J; Kim, KR; Koh, YW; Kim, SH; Choi, EC; Yoon, SO; Shim, HS; Paik, S; Kim, TM; Cho, BC
    View PubMed
  • LUNG CANCER 2020 10.1016/j.lungcan.2020.05.035 Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer Jung1, HA; Noh, JM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Pyo, H; Ahn, YC; Park, K
    View PubMed
  • EXPERT OPIN INV DRUG 2020 10.1080/13543784.2020.1804855 Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors Kim1, S; Kim, S; Park, YS; Park, JO; Lim, HY; Ahn, JS; Lee, J; Sun, JM; Kang, WK; Han, R; Kim, J; Ahn, MJ
    View PubMed
  • LUNG CANCER 2020 10.1016/j.lungcan.2020.05.033 Ten-year patient journey of stage III non-small cell lung cancer patients A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study) Jung1, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • BMC CANCER 2020 10.1186/s12885-020-07214-4 Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer real-world data in Korea Kim1, H; Kwon, M; Kim, B; Jung, HA; Sun, JM; Lee, SH; Park, K; Ahn, MJ
    View PubMed
  • EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932 Evaluating entrectinib as a treatment option for non-small cell lung cancer Lee1, JY; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.04.004 HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients Shim1, JH; Kim, HS; Cha, H; Kim, S; Kim, TM; Anagnostou, V; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH
    View PubMed
  • J THORAC DIS 2020 10.21037/jtd.2019.08.29 Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer? Lee1, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER 2020 10.1002/cncr.32809 Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer Lee1, J; Kim, HS; Lee, B; Kim, HK; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • EUR J CANCER 2020 10.1016/j.ejca.2020.03.029 Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma Lee1, J; La Choi, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • IN VIVO 2020 10.21873/invivo.11920 Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping Hur1, JY; Ku, BM; Shim, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • Journal of thoracic disease 2020 10.21037/jtd.2020.03.23 Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery Shin1, S; Kim, HK; Cho, JH; Choi, YS; Kim, K; Kim, J; Zo, JI; Sun, JM; Ahn, MJ; Park, K; Pyo, H; Ahn, YC; Shim, YM
    View PubMed
  • NAT COMMUN 2020 10.1038/s41467-020-16164-1 Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Kim1, N; Kim, HK; Lee, K; Hong, Y; Cho, JH; Choi, JW; Lee, J; Suh, YL; Ku, BM; Eum, HH; Choi, S; Choi, YL; Joung, JG; Park, WY; Jung, HA; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Lee, HO
    View PubMed
  • CANCERS 2020 10.3390/cancers12040925 Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer Yoon1, HG; Oh, D; Ahn, YC; Noh, JM; Pyo, H; Cho, WK; Song, YM; Park, M; Hwang, NY; Sun, JM; Kim, HK; Zo, JI; Shim, YM
    View PubMed
  • INVEST NEW DRUG 2020 10.1007/s10637-019-00795-3 Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer Ku1, BM; Bae, YH; Lee, KY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J CLIN ONCOL 2020 10.1200/JCO.19.00931 Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) Cho1, JH; Lim, SH; An, HJ; Kim, KH; Park, KU; Kang, EJ; Choi, YH; Ahn, MS; Lee, MH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • Cancer Med 2020 10.1002/cam4.2868 PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence Byeon1, S; Cho, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • Oncoimmunology 2020 10.1080/2162402X.2020.1722023 Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment Kim1, KH; Hur, JY; Cho, J; Ku, BM; Koh, J; Koh, JY; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Shin, EC
    View PubMed
  • BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9 Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors Shin1, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2019.186 Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea Lee1, K; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahm, MJ
    View PubMed
  • LANCET ONCOL 2019 10.1016/S1470-2045(19)30504-2 Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study Ahn1, MJ; Han, JY; Lee, KH; Kim, SW; Kim, DW; Lee, YG; Cho, EK; Kim, JH; Lee, GW; Lee, JS; Min, YJ; Kim, JS; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Kim, HT; Lee, DH; Kim, S; Cho, BC
    View PubMed
  • INT J CANCER 2019 10.1002/ijc.32235 Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease Shin1, SH; Park, HY; Im, Y; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, HY; Lee, SH
    View PubMed
  • EUR J CANCER 2019 10.1016/j.ejca.2019.08.001 Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing Kim1, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-50574-6 Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab Eun1, Y; Kim, IY; Sun, JM; Lee, J; Cha, HS; Koh, EM; Kim, H; Lee, J
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.014 DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC Park1, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • NAT COMMUN 2019 10.1038/s41467-019-12159-9 DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load Jung1, H; Kim, HS; Kim, JY; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Esteller, M; Lee, SH; Choi, JK
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.033 Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Kim1, Y; Kim, CH; Lee, HY; Lee, SH; Kim, HS; Lee, S; Cha, H; Hong, S; Kim, K; Seo, SW; Sun, JM; Ahn, MJ; Ahn, JS; Park, K
    View PubMed
  • KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.234 Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Kim1, MJ; Kim, SM; Jung, HA; Hong, JY; Chang, WJ; Choi, MK; Kim, HS; Sun, JM; Park, K; Ahn, MJ
    View PubMed
  • LUNG CANCER 2019 10.1016/j.lungcan.2019.05.024 Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma Park1, S; Shim, JH; Lee, B; Cho, I; Park, WY; Kim, Y; Lee, SH; Choi, YL; Han, J; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • EUR J NUCL MED MOL I 2019 10.1007/s00259-019-04387-4 Diagnostic value of surveillance F-18-fluorodeoxyglucose PET/CT for detecting recurrent esophageal carcinoma after curative treatment Kim1, SJ; Hyun, SH; Moon, SH; Lee, KS; Sun, JM; Oh, D; Ahn, YC; Zo, JI; Shim, YM; Choi, JY
    View PubMed
  • J CLIN ONCOL 2019 10.1200/JCO.2017.77.3184 Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial Cho1, J; Kim, HS; Ku, BM; Choi, YL; Cristescu, R; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-48674-4 Predictive and Prognostic Value of F-18-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer Moon1, SH; Sun, JM; Ahn, JS; Park, K; Kim, BT; Lee, KH; Ahn, MJ; Choi, JY
    View PubMed
  • J CANCER RES CLIN 2019 10.1007/s00432-019-02889-0 Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma Cho1, JH; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • J IMMUNOTHER CANCER 2019 10.1186/s40425-019-0609-x Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma Park1, S; Joung, JG; Min, YW; Nam, JY; Ryu, D; Oh, D; Park, WY; Lee, SH; Choi, YL; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.020 Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor Lee1, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ
    View PubMed
  • FUTURE ONCOL 2019 10.2217/fon-2018-0609 KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer Kato1, K; Shah, MA; Enzinger, P; Bennouna, J; Shen, L; Adenis, A; Sun, JM; Cho, BC; Ozguroglu, M; Kojima, T; Kostorov, V; Hierro, C; Zhu, Y; McLean, LA; Shah, S; Doi, T
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.125 EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy Park1, SE; Noh, JM; Kim, YJ; Lee, HS; Cho, JH; Lim, SW; Ahn, YC; Pyo, H; Choi, YL; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • RADIOTHER ONCOL 2019 10.1016/j.radonc.2019.01.005 Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery Cho1, WK; Oh, D; Kim, HK; Ahn, YC; Noh, JM; Shim, YM; Zo, JI; Choi, YS; Sun, JM; Lee, SH; Ahn, MJ; Park, K; Nam, H
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.151 Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea Byeon1, S; Kim, Y; Lim, SW; Cho, JH; Park, S; Lee, J; Sun, JM; Choi, YL; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.324 A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13 Yoo1, KH; Lee, SJ; Cho, J; Lee, KH; Park, KU; Kim, KH; Cho, EK; Choi, YH; Kim, HR; Kim, HG; Ahn, HJ; Lee, HY; Yun, HJ; Kang, JH; Jeong, J; Choi, MY; Jung, SH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • LUNG CANCER 2019 10.1016/j.lungcan.2019.01.012 Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer Lee1, K; Kim, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Sun, JM
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.117 Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib Kim1, Y; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.366 Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer Lee1, KH; Ahn, YC; Pyo, H; Noh, JM; Park, SG; Kim, TG; Lee, E; Nam, H; Lee, H; Sun, JM; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • CLIN CANCER RES 2019 10.1158/1078-0432.CCR-18-1449 The First-week Proliferative Response of Peripheral Blood PD-1(+)CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors Kim1, KH; Cho, J; Ku, BM; Koh, J; Sun, JM; Lee, SH; Ahn, JS; Cheon, J; Min, YJ; Park, SH; Park, K; Ahn, MJ; Shin, EC
    View PubMed
  • CLIN NUCL MED 2019 10.1097/RLU.0000000000002394 Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer FDG Uptake and Risk Stratification Moon1, SH; Sun, JM; Ahn, JS; Park, K; Ahn, MJ; Choi, JY
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2018.10.150 Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC Kim1, Y; Lee, B; Shim, JH; Lee, SH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.138 Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer Lee1, J; Shim, JH; Park, WY; Kim, HK; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • LUNG CANCER 2019 10.1016/j.lungcan.2018.11.027 Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor Park1, S; Han, J; Sun, JM
    View PubMed
  • RADIAT ONCOL 2018 10.1186/s13014-018-1196-6 Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion Kim1, H; Oh, D; Ahn, YC; Park, K; Ahn, MJ; Lee, SH; Sun, JM; Shim, YM; Zo, JI; Choi, YS; Kim, HK; Cho, JH
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2018.08.003 Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial Lim1, SW; Park, S; Kim, Y; Cho, JH; Park, SE; Lee, H; Kim, HK; Kim, SM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2018.05.026 Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice Park1, S; Ahn, BC; Lim, SW; Sun, JM; Kim, HR; Hong, MH; Lee, SH; Ahn, JS; Park, K; La Choi, Y; Cho, BC; Ahn, MJ
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2018.06.009 Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma Lee1, J; Jung, HA; Kim, Y; Choi, S; Han, J; Choi, YL; Lee, SH; Ahn, JS; Park, K; Sun, JM
    View PubMed
  • Cancer Med 2018 10.1002/cam4.1617 Surgically resected T1-and T2-stage esophageal squamous cell carcinoma: T and N staging performance of EUS and PET/CT Jeong1, DY; Kim, MY; Lee, KS; Choi, JY; Kim, SJ; Chung, MJ; Min, YW; Kim, HK; Zo, JI; Shim, YM; Sun, JM
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2018.04.038 Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication Lee1, H; Lee, HY; Sun, JM; Lee, SN; Kim, Y; Park, SE; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • SCI REP-UK 2018 10.1038/s41598-018-27273-9 Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach Lee1, SW; Park, H; Lee, HY; Sohn, I; Lee, SH; Kang, J; Sun, JM; Ahn, MJ
    View PubMed
  • Clin Pharmacol Drug Dev 2018 10.1002/cpdd.427 Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC Tan1, EH; Lim, WT; Ahn, MJ; Ng, QS; Ahn, JS; Tan, DSW; Sun, JM; Han, M; Payumo, FC; Mckee, K; Yin, W; Credi, M; Agarwal, S; Jac, J; Park, K
    View PubMed
  • PLoS One 2018 10.1371/journal.pone.0196808 Role of F-18-FDG PET/CT in patients without known primary malignancy with skeletal lesions suspicious for cancer metastasis Park1, SB; Park, JM; Moon, SH; Cho, YS; Sun, JM; Kim, BT; Lee, KH
    View PubMed
  • PLoS One 2018 10.1371/journal.pone.0194730 Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model Ku1, BM; Choi, MK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2017.11.122 Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer" Sun1, JM
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.007 Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer Cho1, JH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.014 KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma Cho1, JH; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • BRIT J CANCER 2018 10.1038/bjc.2017.465 Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07) Sun1, JM; Lee, KH; Kim, BS; Kim, HG; Min, YJ; Yi, SY; Yun, HJ; Jung, SH; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2018.01.004 Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy Park1, BJ; Cho, JH; Lee, JH; Shin, S; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Kim, J
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.011 Increased Response Rates to Salvage Chemotherapy Administered after PD-1 /PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer Park1, SE; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • CANCER RES TREAT 2018 10.4143/crt.2016.591 Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer Cho1, JH; Zhou, W; Choi, YL; Sun, JM; Choi, H; Kim, TE; Dolled-Filhart, M; Emancipator, K; Rutkowski, MA; Kim, J
    View PubMed
  • INVEST NEW DRUG 2017 10.1007/s10637-017-0463-y Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors Lee1, SJ; Lee, SY; Lee, WS; Yoo, JS; Sun, JM; Lee, J; Park, SH; Park, JO; Ahn, MJ; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • J THORAC ONCOL 2017 10.1016/j.jtho.2017.09.1954 Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer Sun1, JM; Noh, JM; Oh, D; Kim, HK; Lee, SH; Choi, YS; Pyo, H; Ahn, JS; Jung, SH; Ahn, YC; Kim, J; Ahn, MJ; Zo, JI; Shim, YM; Park, K
    View PubMed
  • CLIN LUNG CANCER 2017 10.1016/j.cllc.2017.04.008 Programmed Death Ligand 1 Expression in Paired Non-Small-Cell Lung Cancer Tumor Samples Cho1, JH; Sorensen, SF; Choi, YL; Feng, Y; Kim, TE; Choi, H; Georgsen, JB; Dolled-Filhart, M; Emancipator, K; Meldgaard, P; Sun, JM; Kim, HK; Choi, YS; Shim, YM; Zhou, W; Hager, H; Kim, J
    View PubMed
  • CANCER RES TREAT 2017 10.4143/crt.2016.442 Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience Park1, H; Oh, D; Ahn, YC; Pyo, H; Noh, JM; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Kim, HK; Choi, YS; Kim, J; Zo, JI; Shim, YM
    View PubMed
  • EXPERT REV MOL DIAGN 2017 10.1080/14737159.2017.1372196 An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer Ku1, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2017 10.4143/crt.2016.424 Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer Lee1, MY; Ku, BM; Kim, HS; Lee, JY; Lim, SH; Sun, JM; Lee, SH; Park, K; Oh, YL; Hong, M; Jeong, HS; Son, YI; Baek, CH; Ahn, MJ
    View PubMed
  • CANCER CHEMOTH PHARM 2017 10.1007/s00280-017-3396-4 Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors Kim1, HK; Heo, MH; Lee, HS; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • ONCOTARGET 2017 Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer Ku1, BM; Bae, YH; Koh, J; Sun, JM; Lee, SSH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2017 10.4143/crt.2016.417 A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma Lim1, SH; Shim, YM; Park, SH; Kim, HK; Choi, YS; Ahn, MJ; Park, K; Zo, JI; Sun, JM
    View PubMed
  • Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8. EGFR TKI combination with immunotherapy in non-small cell lung cancer Ahn MJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1.
    View PubMed
  • Curr Opin Oncol. 2017 Mar;29(2):89-96. doi: 10.1097/CCO.0000000000000350. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer? Sun JM11, Park K.
    View PubMed
  • RADIOTHERAPY AND ONCOLOGY, FEB 2017, 122(2):217-223, DOI: 10.1016/j.radonc.2016.09.015 A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer Lee JY1, Sun JM, Oh D, Lim SH, Chi S, Lee SH, Jung SH, Ahn MJ, Ahn YC, Park K
    View PubMed
  • Expert Opin Pharmacother. 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283. Osimertinib for the treatment of non-small cell lung cancer Sun JM11, Lee SH1, Ahn JS1, Park K1, Ahn MJ1.
    View PubMed
  • Oncotarget. 2017 Feb 28;8(9):15943-15951. doi: 10.18632/oncotarget.13056. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) Kim HR11, Jang JS2, Sun JM3, Ahn MJ3, Kim DW4, Jung I5, Lee KH6, Kim JH1, Lee DH7, Kim SW, Cho BC1.
    View PubMed
  • Oncotarget. 2017 Jan 10;8(2):3542-3552. doi: 10.18632/oncotarget.12200. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery Cho WK11, Oh D1, Ahn YC1, Shim YM2, Zo JI2, Sun JM3, Ahn MJ3, Park K3.
    View PubMed
  • J Thorac Oncol. 2016 Dec;11(12):2202-2207. doi: 10.1016/j.jtho.2016.07.005. Epub 2016 Jul 14. Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease? Kim H11, Ahn YC2, Pyo H1, Oh D1, Noh JM1, Sun JM3, Ahn JS3, Ahn MJ3, Park K3, Choi YS4, Kim J4, Zo JI4, Shim YM4, Lee M5, Han J5.
    View PubMed
  • J Thorac Oncol. 2016 Dec;11(12):2051-2052. doi: 10.1016/j.jtho.2016.09.130. Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision Ahn MJ11, Sun JM2, Lee SH2, Ahn JS2, Park K2.
    View PubMed
  • J Thorac Dis. 2016 Nov;8(11):3175-3186. doi: 10.21037/jtd.2016.11.25. The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations Cha YK11, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Choi YL4, Lee KS2.
    View PubMed
  • World Neurosurg. 2016 Nov;95:399-405. doi: 10.1016/j.wneu.2016.08.046. Epub 2016 Aug 24. Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer Choi JW11, Kong DS1, Seol HJ1, Nam DH1, Yoo KH2, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Lee JI3.
    View PubMed
  • Sci Rep. 2016 Nov 28;6:37392. doi: 10.1038/srep37392. Vertical Magnetic Separation of Circulating Tumor Cells for Somatic Genomic-Alteration Analysis in Lung Cancer Patients Yoo CE11,2, Park JM3, Moon HS1,2, Joung JG2, Son DS1,2, Jeon HJ2, Kim YJ1,2, Han KY1,2, Sun JM4, Park K4, Park D1,2, Park WY2,5.
    View PubMed
  • Cancer. 2016 Oct;122(19):3024-31. doi: 10.1002/cncr.30135. Epub 2016 Jun 17. Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study Lim SH11, Sun JM1, Choi YL2, Kim HR3, Ahn S2, Lee JY1, Lee SH1, Ahn JS1, Park K1, Kim JH3, Cho BC4, Ahn MJ5.
    View PubMed
  • Lung Cancer. 2016 Oct;100:24-29. doi: 10.1016/j.lungcan.2016.07.025. Epub 2016 Jul 26. Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor Moon SH11, Kim HS2, Cho YS1, Sun JM3, Ahn JS3, Park K3, Kim BT1, Ahn MJ4, Lee KH5.
    View PubMed
  • Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells Ku BM11, Bae YH1, Koh J1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3,4.
    View PubMed
  • Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis Byeon S11, Ham JS1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.
    View PubMed
  • J Thorac Oncol. 2016 Jul;11(7):1003-11. doi: 10.1016/j.jtho.2016.04.007. Epub 2016 Apr 18. Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases Sun JM11, Zhou W2, Choi YL1, Choi SJ1, Kim SE1, Wang Z2, Dolled-Filhart M2, Emancipator K2, Wu D2, Weiner R2, Frisman D3, Kim HK1, Choi YS1, Shim YM1, Kim J4.
    View PubMed
  • Lung Cancer. 2016 Jun;96:48-51. doi: 10.1016/j.lungcan.2016.03.012. Epub 2016 Mar 26. Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria Kim HS11, Lee JY2, Lim SH2, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.
    View PubMed
  • Clin Cancer Res. 2016 May 15;22(10):2386-95. doi: 10.1158/1078-0432.CCR-15-1260. Epub 2016 Jan 8. Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686) Karlovich C11, Goldman JW2, Sun JM3, Mann E1, Sequist LV4, Konopa K5, Wen W6, Angenendt P7, Horn L8, Spigel D9, Soria JC10, Solomon B11, Camidge DR12, Gadgeel S13, Paweletz C14, Wu L6, Chien S6, O'Donnell P6, Matheny S1, Despain D1, Rolfe L1, Raponi M1, Allen AR1, Park K3, Wakelee H15.
    View PubMed
  • Clin Cancer Res. 2016 May 1;22(9):2139-45. doi: 10.1158/1078-0432.CCR-15-1653. Epub 2015 Dec 14. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib Lee JY11, Sun JM1, Lim SH1, Kim HS, Yoo KH1, Jung KS1, Song HN1, Ku BM2, Koh J2, Bae YH2, Lee SH1, Ahn JS1, Park K1, Ahn MJ3.
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):527-36. doi: 10.4143/crt.2015.249. Epub 2015 Sep 15. Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma Kim HS11, Lee JY1, Lim SH1, Park K1, Sun JM1, Ko YH2, Baek CH3, Son YI3, Jeong HS3, Ahn YC4, Lee MY5, Hong M6, Ahn MJ1.
    View PubMed
  • Head Neck. 2016 Apr;38 Suppl 1:E293-9. doi: 10.1002/hed.23988. Epub 2015 Jun 26. Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy Chang JH11,2, Ahn YC1, Park H1, Oh D1, Noh JM1, Sun JM3, Ahn MJ3, Park K3.
    View PubMed
  • Oncotarget. 2016 Mar 22;7(12):14803-13. doi: 10.18632/oncotarget.7543. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma Ku BM11, Yi SY2, Koh J1, Bae YH1, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.
    View PubMed
  • Cancer Imaging. 2016 Mar 16;16:5. doi: 10.1186/s40644-016-0063-7. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study Lee JH11, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Lee KS1.
    View PubMed
  • EXPERT OPINION ON BIOLOGICAL THERAPY, MAR 3 2016, 16(3):397-406 , DOI: 10.1517/14712598.2016.1145652 Pembrolizumab for the treatment of non-small cell lung cancer Lim SH1, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ
    View PubMed
  • Clin Genitourin Cancer. 2016 Feb;14(1):76-81. doi: 10.1016/j.clgc.2015.09.008. Epub 2015 Sep 25. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma Kim YS11, Lee SI2, Park SH3, Park S3, Hwang IG4, Lee SC5, Sun JM3, Lee J3, Lim HY3.
    View PubMed
  • Radiother Oncol. 2016 Feb;118(2):244-50. doi: 10.1016/j.radonc.2015.11.030. Epub 2015 Dec 17. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02) Lee JY11, Sun JM1, Oh DR2, Lim SH1, Goo J3, Lee SH1, Kim SB4, Park KU5, Kim HK6, Hong DS7, Kim JS8, Kim SG9, Yi SY10, Yun HJ11, Hyun MS12, Kim HJ13, Jung SH3, Park K1, Ahn YC14, Ahn MJ15.
    View PubMed
  • Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) Lee JY11, Qing X2, Xiumin W2, Yali B2, Chi S3, Bak SH4, Lee HY5, Sun JM1, Lee SH1, Ahn JS1, Cho EK6, Kim DW7, Kim HR8, Min YJ9, Jung SH3, Park K1, Mao M2, Ahn MJ1.
    View PubMed
  • Support Care Cancer. 2016 Jan;24(1):301-9. doi: 10.1007/s00520-015-2783-9. Epub 2015 Jun 4. Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects Hwang IG11, Kang JH2, Oh SY3,4, Lee S5, Kim SH5, Song KH6, Son C7, Park MJ8, Kang MH2, Kim HG2, Lee J9, Park YS9, Sun JM9, Kim HJ10, Kim CK10, Yi SY11, Jang JS1, Park K12,13, Kim HJ5.
    View PubMed
  • Jpn J Clin Oncol. 2016 Jan;46(1):40-5. doi: 10.1093/jjco/hyv163. Epub 2015 Nov 10. Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy Lim SH11, Lee SJ1, Ahn MJ1, Park K1, Sun JM2.
    View PubMed
  • Eur J Cancer. 2016 Jan;52:1-9. doi: 10.1016/j.ejca.2015.09.019. Epub 2015 Nov 26. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer Lim SH11, Hong M2, Ahn S3, Choi YL3, Kim KM3, Oh D4, Ahn YC4, Jung SH5, Ahn MJ1, Park K1, Zo JI6, Shim YM6, Sun JM7.
    View PubMed
  • Biomaterials. 2016 Jan;75:271-8. doi: 10.1016/j.biomaterials.2015.10.033. Epub 2015 Oct 23. Highly dense, optically inactive silica microbeads for the isolation and identification of circulating tumor cells Yoo CE11, Moon HS1, Kim YJ1, Park JM1, Park D1, Han KY1, Park K2, Sun JM2, Park WY3.
    View PubMed
  • J Thorac Oncol. 2015 Dec;10(12):1800-6. doi: 10.1097/JTO.0000000000000692. A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors Kim HS11, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.
    View PubMed
  • Oncotarget. 2015 Dec 29;6(42):44971-84. doi: 10.18632/oncotarget.6056. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma Kim HS11, Kim SM2, Kim H3, Pyo KH2, Sun JM4, Ahn MJ4, Park K4, Keam B5, Kwon NJ6, Yun HJ7, Kim HG8, Chung IJ9, Lee JS10, Lee KH11, Kim DJ12, Lee CG13, Hur J14, Chung H15, Park JC15, Shin SK15, Lee SK15, Kim HR1, Moon YW1, Lee YC15, Kim JH1, Paik S16,17, Cho BC1.
    View PubMed
  • Lung Cancer. 2015 Nov;90(2):261-6. doi: 10.1016/j.lungcan.2015.08.020. Epub 2015 Sep 4. Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs Lee SJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1, Ahn MJ2.
    View PubMed
  • J Neurooncol. 2015 Nov;125(2):331-8. doi: 10.1007/s11060-015-1915-x. Epub 2015 Sep 15. Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer Cho KR11, Lee MH1, Kong DS1, Seol HJ1, Nam DH1, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Kim ST3, Lim do H4, Lee JI5.
    View PubMed
  • ONCOTARGET, OCT 13 2015, 6(31), 30929-30938, 10.18632/oncotarget.5131 Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer Park S1, Langley E, Sun JM, Lockton S, Ahn JS, Jain A, Park K, Singh S, Kim P, Ahn MJ
    View PubMed
  • Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.
    View PubMed
  • Cancer Res Treat. 2015 Oct;47(4):645-52. doi: 10.4143/crt.2014.144. Epub 2015 Feb 12. Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer Noh JM11, Ahn YC1, Lee H2, Pyo H1, Kim B1, Oh D1, Park H1, Lee E1, Park K3, Ahn JS3, Ahn MJ3, Sun JM3.
    View PubMed
  • J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04 Ahn JS11, Ahn YC1, Kim JH1, Lee CG1, Cho EK1, Lee KC1, Chen M1, Kim DW1, Kim HK1, Min YJ1, Kang JH1, Choi JH1, Kim SW1, Zhu G1, Wu YL1, Kim SR1, Lee KH1, Song HS1, Choi YL1, Sun JM1, Jung SH1, Ahn MJ1, Park K2.
    View PubMed
  • Eur J Cancer. 2015 Aug;51(12):1588-95. doi: 10.1016/j.ejca.2015.05.020. Epub 2015 Jun 9. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer Lim SM11, Chung WY2, Nam KH2, Kang SW2, Lim JY3, Kim HG4, Shin SH5, Sun JM6, Kim SG7, Kim JH1, Kang CW8, Kim HR9, Cho BC10.
    View PubMed
  • J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29. Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial Sun JM11, Ahn JS1, Jung SH1, Sun J1, Ha SY1, Han J1, Park K1, Ahn MJ2.
    View PubMed
  • PLoS Genet. 2015 Aug 21;11(8):e1005467. doi: 10.1371/journal.pgen.1005467. eCollection 2015. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer Ji JH11, Oh YL2, Hong M2, Yun JW3, Lee HW2, Kim D4, Ji Y4, Kim DH4, Park WY3, Shin HT3, Kim KM2, Ahn MJ5, Park K5, Sun JM5.
    View PubMed
  • J Thorac Oncol. 2015 Jun;10(6):903-9. doi: 10.1097/JTO.0000000000000535. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors Lee JY11, Ku BM, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Cancer Chemother Pharmacol. 2015 Jun;75(6):1229-36. doi: 10.1007/s00280-015-2740-9. Epub 2015 Apr 23. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test Choi MK11, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Head Neck. 2015 May;37(5):E66-9. doi: 10.1002/hed.23884. Epub 2015 Mar 29. Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series Kim SM11, Kim MJ, Jung HA, Sun JM, Choi YL, Ko YH, Park K, Baek CH, Son YI, Ahn MJ.
    View PubMed
  • World J Gastroenterol. 2015 Apr 14;21(14):4268-74. doi: 10.3748/wjg.v21.i14.4268. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma Lee MY11, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim do H1, Lee SI1, Park KW1.
    View PubMed
  • Ann Oncol. 2015 Apr;26(4):762-8. doi: 10.1093/annonc/mdu584. Epub 2014 Dec 23. A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer Lim SH11, Lee JY1, Lee MY1, Kim HS1, Lee J1, Sun JM1, Ahn JS1, Um SW2, Kim H2, Kim BS3, Kim ST4, Na DL5, Sun JY6, Jung SH7, Park K1, Kwon OJ2, Lee JI3, Ahn MJ8.
    View PubMed
  • World J Gastroenterol. 2015 Apr 14;21(14):4268-74. doi: 10.3748/wjg.v21.i14.4268. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma Lee MY11, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim DH1, Lee SI1, Park KW1.
    View PubMed
  • Pharmacogenomics. 2015;16(4):383-91. doi: 10.2217/pgs.15.14. Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients Woo HI11, Kim JA, Jung HA, Kim KK, Lee JY, Sun JM, Ahn JS, Park K, Lee SY, Ahn MJ.
    View PubMed
  • Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25. Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Kim HS11, Kwon HJ2, Jung I3, Yun MR4, Ahn MJ5, Kang BW6, Sun JM5, Kim SB7, Yoon DH7, Park KU8, Lee SH9, Koh YW10, Kim SH10, Choi EC10, Koo DH11, Sohn JH12, Kim B13, Kwon NJ14, Yun HJ15, Lee MG16, Lee JH17, Kim TM18, Kim HR19, Kim JH19, Paik S20, Cho BC21.
    View PubMed
  • Lung Cancer. 2015 Feb;87(2):148-54. doi: 10.1016/j.lungcan.2014.11.013. Epub 2014 Nov 29. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea Baek JH11, Sun JM2, Min YJ3, Cho EK4, Cho BC5, Kim JH5, Ahn MJ2, Park K2.
    View PubMed
  • Invest New Drugs. 2015 Feb;33(1):12-21. doi: 10.1007/s10637-014-0163-9. Epub 2014 Oct 25. BYL719, a selective inhibitor of phosphoinositide 3-Kinase alpha, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer Ku BM11, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Ann Oncol. 2015 Jan;26(1):161-6. doi: 10.1093/annonc/mdu504. Epub 2014 Oct 29. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing Sun JM11, Choi YL2, Ji JH3, Ahn JS1, Kim KM2, Han J2, Ahn MJ1, Park K4.
    View PubMed
  • Lancet Oncol. 2014 Oct;15(11):1254-62. doi: 10.1016/S1470-2045(14)70402-4. Epub 2014 Sep 14. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data Rossi A11, Chiodini P2, Sun JM3, O'Brien ME4, von Plessen C5, Barata F6, Park K3, Popat S4, Bergman B7, Parente B8, Gallo C2, Gridelli C9, Perrone F10, Di Maio M10.
    View PubMed
  • Ann Oncol. 2014 Sep;25(9):1866. doi: 10.1093/annonc/mdu244. Epub 2014 Jul 15. Letter to the editor on 'Phase III trial of concurrent thoracic radiotherapy with either first-or third-cycle chemotherapy for limited-disease small cell lung cancer' Park K11, Sun JM2.
    View PubMed
  • Oncologist. 2014 Jul;19(7):702-3. doi: 10.1634/theoncologist.2013-0419. Epub 2014 May 27. Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR Ahn MJ11, Kim SW2, Cho BC3, Ahn JS1, Lee DH2, Sun JM4, Massey D5, Kim M6, Shi Y7, Park K8.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Jun;73(6):1217-25. doi: 10.1007/s00280-014-2458-0. Epub 2014 Apr 3. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease Choi MK11, Hong JY, Chang W, Kim M, Kim S, Jung HA, Lee SJ, Park S, Chung MP, Sun JM, Park K, Ahn MJ, Ahn JS.
    View PubMed
  • Ann Surg Oncol. 2014 Jun;21(6):2083-90. doi: 10.1245/s10434-014-3540-x. Epub 2014 Feb 13. Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy Lee H11, Ahn YC, Pyo H, Kim B, Oh D, Nam H, Lee E, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 May;73(5):1063-70. doi: 10.1007/s00280-014-2442-8. Epub 2014 Mar 25. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs Lee JY11, Lim SH, Kim M, Kim S, Jung HA, Chang WJ, Choi MK, Hong JY, Lee SJ, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095. Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21 Lim SH11, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Lung Cancer. 2014 Apr;84(1):51-5. doi: 10.1016/j.lungcan.2014.01.017. Epub 2014 Jan 28. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin Chang WJ11, Sun JM2, Lee JY1, Ahn JS1, Ahn MJ1, Park K1.
    View PubMed
  • Chemotherapy. 2014;60(2):73-80. doi: 10.1159/000368071. Epub 2014 Nov 29. Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer Jung HA11, Sun JM, Park SH, Kwon GY, Lim HY.
    View PubMed
  • Eur J Cancer. 2014 Mar;50(4):746-52. doi: 10.1016/j.ejca.2013.11.029. Epub 2013 Dec 11. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency Kim KH11, Kim HY2, Kim HR3, Sun JM4, Lim HY4, Lee HJ5, Lee S6, Bae WK7, Rha SY8; Korean Cancer Study Group; Genitourinary & Gynecology Cancer Committee.
    View PubMed
  • Lung Cancer. 2014 Mar;83(3):411-5. doi: 10.1016/j.lungcan.2013.12.015. Epub 2014 Jan 7. Pleural epithelioid hemangioendothelioma harboring CAMTA1 rearrangement Ha SY11, Choi IH1, Han J2, Choi YL1, Cho JH3, Lee KJ4, Sun JM5.
    View PubMed
  • Lung Cancer. 2014 Feb;83(2):259-64. doi: 10.1016/j.lungcan.2013.11.009. Epub 2013 Nov 20. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma Sun JM11, Lira M2, Pandya K2, Choi YL3, Ahn JS1, Mao M2, Han J3, Park K1, Ahn MJ4, Kim J5.
    View PubMed
  • J Clin Oncol. 2014 Jan 10;32(2):121-8. doi: 10.1200/JCO.2013.50.8556. Epub 2013 Dec 9. Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients Kim Y11, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, Oh IJ, Kim HK, Choi YS, Kim K, Shim YM, Kim KS, Song SY, Na KJ, Choi YL, Hayes DN, Kim J, Cho S, Kim YC, Ahn JS, Ahn MJ, Getz G, Meyerson M, Park K.
    View PubMed
  • Int J Oncol. 2014 Jan;44(1):5-16. doi: 10.3892/ijo.2013.2181. Epub 2013 Nov 15. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review Oh WK11, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS.
    View PubMed
  • Urol Oncol. 2014 Jan;32(1):49.e23-31. doi: 10.1016/j.urolonc.2013.07.015. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy Sung JY11, Sun JM2, Chang Jeong B3, Il Seo S3, Soo Jeon S3, Moo Lee H3, Yong Choi H3, Young Kang S4, Choi YL5, Young Kwon G6.
    View PubMed
  • Lung Cancer. 2013 Nov;82(2):294-8. doi: 10.1016/j.lungcan.2013.08.023. Epub 2013 Sep 3. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors Sun JM11, Ahn MJ, Choi YL, Ahn JS, Park K.
    View PubMed
  • J Thorac Oncol. 2013 Oct;8(10):e91-2. doi: 10.1097/JTO.0b013e31829d51bd. A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Lim SH11, Lee JY, Sun JM, Kim KM, Ahn JS, Ahn MJ, Park K.
    View PubMed
  • Br J Cancer. 2013 Sep 17;109(6):1482-7. doi: 10.1038/bjc.2013.467. Epub 2013 Aug 20. A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer Sun JM11, Kim JR, Do IG, Lee SY, Lee J, Choi YL, Ahn JS, Ahn MJ, Park K.
    View PubMed
  • Ann Oncol. 2013 Aug;24(8):2088-92. doi: 10.1093/annonc/mdt140. Epub 2013 Apr 16. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer(dagger) Sun JM11, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, Lee DH, Pyo H, Song SY, Jung SH, Jo JS, Jo J, Sohn HJ, Suh C, Lee JS, Kim SW, Park K.
    View PubMed
  • Lung Cancer. 2013 Aug;81(2):231-5. doi: 10.1016/j.lungcan.2013.04.011. Epub 2013 May 14. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer Kim YS11, Sun JM, Ahn JS, Ahn MJ, Park K.
    View PubMed
  • Lung Cancer. 2013 May;80(2):191-6. doi: 10.1016/j.lungcan.2013.01.009. Epub 2013 Feb 4. Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer Sun JM11, Rampal S, Lee G, Lee J, Choi YL, Parasuraman B, Guallar E, Cho J, Shim YM.
    View PubMed
  • PLoS One. 2013 May 28;8(5):e64816. doi: 10.1371/journal.pone.0064816. Print 2013. Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer Sun JM11, Hwang DW, Ahn JS, Ahn MJ, Park K.
    View PubMed
  • PLoS One. 2013;8(2):e56011. doi: 10.1371/journal.pone.0056011. Epub 2013 Feb 28. EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital Choi YL11, Sun JM, Cho J, Rampal S, Han J, Parasuraman B, Guallar E, Lee G, Lee J, Shim YM.
    View PubMed
  • J Mol Diagn. 2013 Jan;15(1):51-61. doi: 10.1016/j.jmoldx.2012.08.006. Epub 2012 Dec 12. Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer Lira ME11, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M.
    View PubMed
  • Cancer. 2012 Dec 15;118(24):6234-42. doi: 10.1002/cncr.27630. Epub 2012 Jun 6. Gefitinib Versus Pemetrexed as Second-Line Treatment in Patients With Nonsmall Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy (KCSG-LU08-01) Sun JM11, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group.
    View PubMed
  • J Thorac Oncol. 2012 Dec;7(12):e36-8. doi: 10.1097/JTO.0b013e318274694e. A Dramatic Response to Crizotinib in a Non-Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK Sun JM11, Choi YL, Won JK, Hirsch FR, Ahn JS, Ahn MJ, Park K.
    View PubMed
  • Lung Cancer. 2012 Aug;77(2):365-70. doi: 10.1016/j.lungcan.2012.04.009. Epub 2012 May 11. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer Sun JM11, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK, Choi YS, Han J, Kim J, Kwon OJ, Shim YM, Park K.
    View PubMed
  • BMC?Cancer.?2012 May 22;12:187. doi: 10.1186/1471-2407-12-187. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy Sun JM11,?Sung JY,?Park SH,?Kwon GY,?Jeong BC,?Seo SI,?Jeon SS,?Lee HM,?Jo J,?Choi HY,?Lim HY.
    View PubMed
  • Cancer Chemother Pharmacol. 2011 Aug;68(2):531-8. doi: 10.1007/s00280-010-1522-7. Epub 2010 Nov 25. Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats Sun JM11, Nam MH, Chung JY, Im B, Lee SY, Suh YL, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Oral Oncol. 2011 Aug;47(8):714-9. doi: 10.1016/j.oraloncology.2011.06.007. Epub 2011 Jun 25. Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck Sun JM11, Jun HJ, Ko YH, Park YH, Ahn YC, Son YI, Baek JH, Park K, Ahn MJ.
    View PubMed
  • J Thorac Oncol. 2011 Aug;6(8):1392-9. doi: 10.1097/JTO.0b013e3182208ea8. Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy Sun JM11, Han J, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):655-60. doi: 10.1016/j.ijrobp.2010.02.061. EXPRESSION OF EXCISION REPAIR CROSS-COMPLEMENTATION GROUP 1 AS PREDICTIVE MARKER FOR NASOPHARYNGEAL CANCER TREATED WITH CONCURRENT CHEMORADIOTHERAPY Sun JM11, Ahn MJ, Park MJ, Lee HY, Ahn JS, Lee S, Kang G, Han J, Son YI, Baek CH, Ahn YC, Park K.
    View PubMed
  • J Cancer Res Clin Oncol. 2011 Apr;137(4):687-94. doi: 10.1007/s00432-010-0928-2. Epub 2010 Jun 16. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients Sun JM11, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Lung Cancer. 2011 Jan;71(1):89-93. doi: 10.1016/j.lungcan.2010.04.003. Epub 2010 Jul 3. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases Sun JM11, Ahn JS, Lee S, Kim JA, Lee J, Park YH, Park HC, Ahn MJ, Ahn YC, Park K.
    View PubMed
  • Lung Cancer. 2010 Sep;69(3):330-6. doi: 10.1016/j.lungcan.2009.11.015. Epub 2009 Dec 14. Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy Sun JM11, Kim TS, Lee J, Park YH, Ahn JS, Kim H, Kwon OJ, Lee KS, Park K, Ahn MJ.
    View PubMed
  • Lung Cancer. 2010 Jul;69(1):105-9. doi: 10.1016/j.lungcan.2009.09.014. Epub 2009 Dec 2. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors Sun JM11, Ahn MJ, Park MJ, Yi JH, Kim TS, Chung MJ, Park YH, Ahn JS, Park K.
    View PubMed
  • J Thorac Oncol. 2010 Apr;5(4):540-5. doi: 10.1097/JTO.0b013e3181d3504d. Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer Implications for Selection of Patients for Maintenance Therapy Sun JM11, Park JO, Won YW, Kim JH, Yun J, Lee J, Park YH, Ahn JS, Ahn MJ, Park K.
    View PubMed